[Evaluation of the hematochemical parameters and bone mineral density of women in physiological menopause treated with hormone replacement therapy with nomegestrol acetate and surgical menopause treated with estrogen replacement. Part II].
OBJECTIVE
The purpose of this paper was to estimate the effectiveness of the use of acetate nomegestrol in relation to indicator hematochemical parameters and bone mineral density (BMD) regarding patients in physiological menopause treated with hormone replacement therapy (HRT), compared to patients in surgical menopause treated with HRT by only administering transdermally hemi hydrate estradiol (estrogen replacement therapy, ERT).


METHODS
Sixty women in menopause for at least 6 months ago, aged between 40 and 55 years, were recruited. Thirty of them were given HRT with acetate nomegestrol, and 30 were given only ERT, because they were subjected to general hysterectomy with bilateral adnexectomy. The standards for inclusion were: level of FSH >or= to 30 UI beta-estradiol <to 50 pg/mL, in women who hadn't had any hormonal treatment for osteoporosis in the last 6 months. The patients were tested at the beginning of therapy, at 3 months and after 12 months.


RESULTS
Both groups at the end of treatment showed an increase in BMD level, whereas haematochemical tests were regular or at least stabilized in a large percentage of patients.


CONCLUSIONS
This research has shown the validity of HRT on BMD, underlining a more noteworthy improvement in the patients' group that used acetate nomegestrol than in those that only used estrogens.
Savoca
S
S
Unità per gli Studi sulla Menopausa, Clinica Ostetrica e Ginecologica II, Dipartimento di Ostetricia, Ginecologia e Scienze Radiologiche, Azienda Ospedaliero-Universitaria, Gaspare Rodolico, Policlinico di Catania, Catania. savoca3@interfree.it
D'Agosta
S
S
Lombardo
G
G
D000328:Adult; D015415:Biomarkers / Q000097:blood; D015519:Bone Density / Q000187:drug effects*; D004958:Estradiol / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy / Q000379:methods; D004967:Estrogens / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D008535:Megestrol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008593:Menopause / Q000097:blood / Q000187:drug effects*; D008875:Middle Aged; D011788:Quality of Life; D016896:Treatment Outcome
D015415:Biomarkers; D004967:Estrogens; C047637:nomegestrol; D004958:Estradiol; D005640:Follicle Stimulating Hormone; D008535:Megestrol